Sanofi/Regeneron's Kevzara Priced To Break Into A Crowded Market

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The partners are looking to create a compelling value proposition for the interleukin-6 inhibitor, approved by FDA to treat moderate to severe RA, by pricing it below the market-leading anti-TNFs.

Sanofi and Regeneron Pharmaceuticals Inc. are looking to break into the crowded rheumatoid arthritis market by establishing a compelling value proposition for the interleukin-6 receptor blocker Kevzara (sarilumab). The wholesale acquisition cost of Kevzara is set at $39,000 per year for both the 200 mg and 150 mg doses, a price that is 30% lower than the two market-leading tumor necrosis factor inhibitors, AbbVie Inc.'s Humira (adalimumab) and Amgen Inc.'s Enbrel (etanercept).

Kevzara also could undercut Roche's entrenched IL-6 inhibitor Actemra (tocilizumab), depending on the dosing that is used, although not...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immunological

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Sanofi/Regeneron’s Dupixent: A First For COPD, But Not The Last

 
• By Jessica Merrill

The IL-4/13 inhibitor was approved in the US for COPD, a blockbuster-sized indication, but the commercial ramp could take time and several competitors are on its heels.

Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1

 
• By Saba Afreen

As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.